# US 2023/0390290 A1 · Treatment of her2 positive cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0390290 A1
- Document ID: US20230390290A1
- Status: Published application
- Kind: A1
- Application number: 18/139,653
- Filed: 2023-04-26
- Published: 2023-12-07
- Earliest claimed: 2017-04-28
- Assignees: Seagen Inc.
- Applicants: Seagen Inc.
- Inventors: Scott Peterson; Luke Walker
- Web page: https://patentgrep.com/patent/US20230390290A1

## CPC

- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.

## Claims

### Claim at position 1

-68. (canceled)

### Claim 69

A method for treating a HER2-positive cancer in a subject, the method comprising administering tucatinib and trastuzumab to the subject, wherein:
the tucatinib is administered in an amount of about 300 mg twice per day; and
the trastuzumab is administered at an amount of about 6 mg to 8 mg per kg of the subject's body weight once every three weeks;
wherein the HER2-positive cancer is selected from the group consisting of: colorectal cancer, gastric cancer, lung cancer, biliary cancer, and esophageal cancer.

### Claim 70 (depends on 69)

The method of claim 69, wherein the tucatinib is administered orally.

### Claim 71 (depends on 69)

The method of claim 69, wherein the trastuzumab is administered orally.

### Claim 72 (depends on 69)

The method of claim 69, wherein the trastuzumab is administered subcutaneously.

### Claim 73 (depends on 69)

The method of claim 69, wherein the HER2-positive cancer is lung cancer.

### Claim 74 (depends on 69)

The method of claim 69, wherein the HER2-positive cancer is lung cancer, and the lung cancer is non-small cell lung cancer.

### Claim 75 (depends on 69)

The method of claim 69, wherein the HER2-positive cancer biliary cancer.

### Claim 76 (depends on 69)

The method of claim 69, wherein the HER2-positive cancer is biliary cancer, and the biliary cancer is cholangiocarcinoma.

### Claim 77 (depends on 69)

The method of claim 69, wherein the HER2-positive cancer is colorectal cancer.

### Claim 78 (depends on 69)

The method of claim 69, wherein the HER2-positive cancer is gastric cancer.

### Claim 79 (depends on 69)

The method of claim 69, wherein the HER2-positive cancer is esophageal cancer.

### Claim 80 (depends on 69)

The method of claim 69, wherein the subject had prior treatment with trastuzumab, pertuzumab, or T-DM1.

### Claim 81 (depends on 69)

The method of claim 69, wherein the HER2-positive cancer comprises a cell that has a wild-type KRAS exon 2 genotype, a wild-type NRAS genotype, or a wild-type BRAF genotype.

### Claim 82 (depends on 69)

The method of claim 69, wherein the subject has a HER2-positive cancer which is relapsed or refractory to a standard of care.

### Claim 83 (depends on 69)

The method of claim 69, wherein treating the subject results in a tumor growth inhibition (TGI) index of at least about 85%.

### Claim 84 (depends on 69)

The method of claim 69, wherein treating the subject results in a TGI index that is greater than the TGI index observed when using an anti-HER2 antibody or tucatinib alone.

### Claim 85 (depends on 69)

The method of claim 69, wherein the subject has one or more adverse events and is further administered an additional therapeutic agent to eliminate or reduce the severity of the one or more adverse events.

### Claim 86 (depends on 69)

The method of claim 69, wherein the subject is at risk of developing one or more adverse events and is further administered an additional therapeutic agent to prevent or reduce the severity of the one or more adverse events.

### Claim 87 (depends on 69)

The method of claim 69, wherein the subject is a human.
